Molecular cloninc and expression, in both COS-1 cells and S. cerevisiae, of a human cytosolic type-IVA cyclic AMP specific phosphodiesterase (hPDE-IVA-h6.1)
References (40)
- et al.
J. biol. Chem.
(1993) - et al.
J. biol. Chem.
(1993) - et al.
Meth. Enzym.
(1991) - et al.
Meth. Enzym.
(1991) - et al.
Meth. Enzym.
(1991) Analyst. Biochem.
(1976)- et al.
Biochim. biophys. Acta
(1973) - et al.
Molec. cell Biol.
(1990) - et al.
Endocr. Rev.
Biochem. Pharmac.
Cell Signal.
Biochem. J.
Biochem. J.
Cited by (40)
Role of a differentially expressed cAMP phosphodiesterase in regulating the induction of resistance against oxidative damage in Leishmania donovani
2009, Free Radical Biology and MedicineCyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents
2006, Pharmacology and TherapeuticsDifferential type 4 cAMP-specific phosphodiesterase (PDE4) expression and functional sensitivity to PDE4 inhibitors among rats, monkeys and humans
2004, Biochemical PharmacologyCitation Excerpt :Functionally, the sensitivity of the various species to PDE4 inhibitors was compared using lipopolysaccharide-induced TNF production in total blood leukocytes, since the TNF production assay is highly sensitive to PDE4 inhibition [25,29,30]. In this assay the three PDE4 inhibitors tested, each with a different mechanism of inhibition [20–25], showed an order of potency identical to the order of PDE4 enzyme activity level (i.e. rat > monkey > human) (Table 3). In addition, a PE-induced renal artery contraction assay was used to further assess the sensitivity to PDE4 inhibitors between rats and humans, in light of the fact that arteriopathy has been considered to be a serious “class effect” of PDE4 inhibitors in rats [5–7].
Disease activated drugs: A new concept for the treatment of asthma
2001, Bioorganic and Medicinal ChemistryCyclic nucleotide phosphodiesterases: Relating structure and function
2000, Progress in Nucleic Acid Research and Molecular Biology
- ‡
Present address: Fisonz Pharmaceuticals, Bakewell Rd, Loughborough LE11 0RH, U.K.
- §
Present address: Zeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire SK10 4TH, U.K.